

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

FUSS BRANDS CORP.

f/k/a China Botanic Pharmaceuticals Inc.

**80 Broad Street
New York, New York 10004**

917-720-3366
www.cbpi-inc.com
info@cbpi-inc.com
6770

Annual Report
For the Period Ending: October 31, 2022
(the "Reporting Period")

As of October 31, 2022 the number of shares outstanding of our Common Stock was:

14,883,665

As of July 31, 2022 the number of shares outstanding of our Common Stock was:

12,531,685

As of October 31, 2022 the number of shares outstanding of our Common Stock was:

14,883,665

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☒ No: ☐

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

¹ "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

Yes: ☐ No: ☒

On February 4, 2021, as a result of a custodianship in Clark County, Nevada, Case Number: A-20-827231-B Custodian Ventures LLC ("Custodian") was appointed custodian of China Botanic Pharmaceutical, Inc. (the "Company"). On the same date, Custodian appointed David Lazar as the Company's Chief Executive Officer, President, Secretary, Chief Financial Officer, Chief Executive Officer, and Chairman of the Board of Directors.

On August 24, 2021, as a result of a private transactions, 1,000,000 shares of Series A-1 Preferred Stock, \$0.001 par value per share (the "Shares") of the Company, were transferred from Custodian Ventures, LLC to Issamar Ginzberg, Israel Moshe Levy, Shmuel Rotbard, and Benjamin Levin (collectively, the "Purchasers"). As a result, the Purchasers became holders of approximately 96% of the voting rights of the issued and outstanding share capital of the Company on a fully-diluted basis of the Company, and became the controlling shareholder. The consideration paid for the Shares was \$250,000. The source of the cash consideration for the Shares was personal funds. In connection with the transaction, David Lazar released the Company from all debts owed to him and/or Custodian Ventures, LLC.

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

June 1997	ComTech Consolidation Group, Inc
February 1999	E-Net Corporation
May 1999	E-Net Financial Corporation
January 2000	E-Net.Com Corporation
February 2000	E-Net Financial.Com Corporation
January 2002	Anza Capital, Inc ("Anza")
June 2006	Renhuang Pharmaceuticals, Inc.
October 2010	China Botanic Pharmaceutical Inc

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

Nevada -active

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

On July 14, 2022, China Botanic Pharmaceuticals Inc. amended its articles of incorporation change its name to Fuss Brands Corp. (the "Name Change"). The change was made in anticipation of entering into a new line of business operations.

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

On July 13, 2022, the Company amended its articles of incorporation to reverse split its common stock at a rate of 1 for 26 (the "Reverse").

On July 22, 2022, FINRA declared the Name Change and the Reverse effective. Also on July 28, 2022, the Company was informed by FINRA that the Company's ticker symbol would be changed to FBDS in twenty business days.

The address(es) of the issuer's principal executive office:

80 Broad Street
New York, New York 10004

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address: ☒

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☒

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

On February 4, 2021, as a result of a custodianship in Clark County, Nevada, Case Number: A-20-827231-B Custodian Ventures LLC ("Custodian") was appointed custodian of China Botanic Pharmaceutical, Inc. (the "Company"). On the same date, Custodian appointed David Lazar as the Company's Chief Executive Officer, President, Secretary, Chief Financial Officer, Chief Executive Officer, and Chairman of the Board of Directors.

2) Security Information

Trading symbol:	FBDS	
Exact title and class of securities outstanding:	Common Stock	
CUSIP:	16890Y104	
Par or stated value:	\$0.001	
Total shares authorized:	1,000,000,000	as of date: 10/31/2022
Total shares outstanding:	14,883,665	as of date: 10/31/2022
Number of shares in the Public Float ² :	718,850	as of date: 10/31/2022
Total number of shareholders of record:	182	as of date: 10/31/2022

All additional class(es) of publicly traded securities (if any):

Trading symbol:	N/A	
Exact title and class of securities outstanding:	_____	
CUSIP:	_____	
Par or stated value:	_____	
Total shares authorized:	_____	as of date: _____
Total shares outstanding:	_____	as of date: _____

² "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

Transfer Agent

Name: Securities Transfer Corporation
Phone: (469) 666 -0101
Email: Inobel@stcttransfer.com
Address: 2901 N. Dallas Parkway, Suite 380 Plano Texas 75093

Is the Transfer Agent registered under the Exchange Act?³ Yes: ☒ No: ☐

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: ☒

Shares Outstanding as of Second Most Recent Fiscal Year End: <u>Opening Balance</u> Date October 31, 2020 Common: 1,432,290 Preferred: -0-			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
6/23/2021	New issuance	1,000,000	Series A Preferred shares	\$0.001	No	Custodian Ventures -David Lazar has voting control	Custodian services	Restricted	4(a)(2)
04/11/2022	Conversion of (53,413) shares of preferred stock to common stock	2,054,347	Common	\$0.001	No	Issamar Ginzberg	Conversion of preferred stock to common stock	Restricted	4(a)(2)

³ To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

04/11/2022	Conversion of (53,413) shares of preferred stock to common stock	2,054,347	Common	\$0.001	No	Shmuel Rotbard	Conversion of preferred stock to common stock	Restricted	4(a)(2)
04/11/2022	Conversion of (53,413) shares of preferred stock to common stock	2,054,347	Common	\$0.001	No	Israel Levy	Conversion of preferred stock to common stock	Restricted	4(a)(2)
04/11/2022	Conversion of (1,862) shares of preferred stock to common stock	71,616	Common	\$0.001	No	Benjamin Levin	Conversion of preferred stock to common stock	Restricted	4(a)(2)
6/21/2022	New Issuance	72,837	Common	\$0.014	Yes	Mordechai Altman	Private Placement	Restricted	Reg D 506(b)
6/22/2022	New Issuance	84,976	Common	\$0.014	Yes	Abraham Barr	Private Placement	Restricted	Reg D 506(b)
7/18/2022	New Issuance	75,990	Common	\$0.014	Yes	Tsvi Brody	Private Placement	Restricted	Reg D 506(b)
7/5/2022	New Issuance	<u>18,202</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Itamar Cohen</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/14/2022	New Issuance	<u>70,481</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Moshe Derli</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/7/2022	New Issuance	<u>48,077</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Arie Dinkel</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/11/2022	<u>New Issuance</u>	<u>43,269</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Netanel Frankenthal</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/15/2022	<u>New Issuance</u>	<u>236,010</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Gravity Capital Partners Ltd. - Brian Sand has voting control</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
6/21/2022	<u>New Issuance</u>	<u>182,091</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Yehoshua Hirschman</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/13/2022	<u>New Issuance</u>	<u>24,231</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Ezra Kaufman</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)

7/7/2022	<u>New Issuance</u>	<u>48,462</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Yitzchak Kaufman</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/5/2022	<u>New Issuance</u>	<u>48,462</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Ben Khasid</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/5/2022	<u>New Issuance</u>	<u>208,750</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Shimon Levenberg</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/14/2022	<u>New Issuance</u>	<u>381,178</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Joseph Levy</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/19/2022	<u>New Issuance</u>	<u>288,462</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>David Lifshitz</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/19/2022	<u>New Issuance</u>	<u>48,269</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>David Nadav</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/5/2022	<u>New Issuance</u>	<u>9,615</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Moshe Ofek</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/5/2022	<u>New Issuance</u>	<u>46,731</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Simcha Povarski</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/17/2022	<u>New Issuance</u>	<u>96,154</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Yosef Raybi</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/14/2022	<u>New Issuance</u>	<u>233,846</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Shlomo Shinkar</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/11/2022	<u>New Issuance</u>	<u>38,846</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Ezra Shtayat</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/6/2022	<u>New Issuance</u>	<u>18,998</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>YaakovStarck</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
6/23/2022	<u>New Issuance</u>	<u>42,500</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Yosef Wasserman</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/6/2022	<u>New Issuance</u>	<u>42,481</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Judah Weiner</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/20/2022	<u>New Issuance</u>	<u>91,038</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Joseph Wexler</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
6/29/2022	<u>New Issuance</u>	<u>1,152,543</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>ATTI LLC - Phillip Goodman has voting control</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/27/2022	<u>New Issuance</u>	<u>30,351</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>EFRAT INVESTMENT - Pinny Rotter has voting control</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)

6/17/2022	<u>New Issuance</u>	<u>24,231</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Aaron Furst</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
6/14/2022	<u>New Issuance</u>	<u>3,606</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Abraham Lerner</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/14/2022	<u>New Issuance</u>	<u>6,070</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Baruch Bindiger</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
6/10/2022	<u>New Issuance</u>	<u>2,423</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Amrom Frankel</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/21/2022	<u>New Issuance</u>	<u>12,115</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Aron Gottenger</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
6/16/2022	<u>New Issuance</u>	<u>90,865</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Avrohom Perlstein</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/7/2022	<u>New Issuance</u>	<u>6,069</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Abe Keys and Co.Corp.-Avrom Schussel has voting control</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
6/2/2022	<u>New Issuance</u>	<u>18,166</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Chevrah Lomdei Mishnah</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/8/2022	<u>New Issuance</u>	<u>19,231</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Dov Klepner</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
6/21/2022	<u>New Issuance</u>	<u>8,413</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Ketov Ltd.</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/6/2022	<u>New Issuance</u>	<u>3,635</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Jonathan Goldstein</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
6/2/2022	<u>New Issuance</u>	<u>3,635</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Joseph Schwartz</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
6/20/2022	<u>New Issuance</u>	<u>120,288</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Joseph Gelbfish</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
6/8/2022	<u>New Issuance</u>	<u>48,462</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Juda Grosz</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
6/15/2022	<u>New Issuance</u>	<u>6,010</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Leah Krausz</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/6/2022	<u>New Issuance</u>	<u>4,846</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Menachem Brecher</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/4/2022	<u>New Issuance</u>	<u>2,404</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Moshe Banda</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/6/2022	<u>New Issuance</u>	<u>12,139</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Shimon Silver</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)

7/4/2022	<u>New Issuance</u>	<u>9,615</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Shlomo Reichman</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/7/2022	<u>New Issuance</u>	<u>4,856</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Yehuda Reichman</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
6/21/2022	<u>New Issuance</u>	<u>12,620</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Yermia Rochlitz</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/5/2022	<u>New Issuance</u>	<u>12,187</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Yitzchok Orzel</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/14/2022	<u>New Issuance</u>	<u>6,070</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Yoel Bindiger</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/14/2022	<u>New Issuance</u>	<u>240,385</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Lazar Schwimmer</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/31/2022	<u>New Issuance</u>	<u>28,846</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Elimelech Sandel</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/20/2022	<u>New Issuance</u>	<u>192,308</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Yanky Grunwald</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/31/2022	<u>New Issuance</u>	<u>180,288</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Shifra Gestetner</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/10/2022	<u>New Issuance</u>	<u>25,000</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Simcha Orlinsky</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/7/2022	<u>New Issuance</u>	<u>6,069</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Amr Baskets - Moshe Rennert has voting control</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/20/2022	<u>New Issuance</u>	<u>12,139</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Yoel Silver</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/4/2022	<u>New Issuance</u>	<u>4,846</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Abraham Orzel</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/13/2022	<u>New Issuance</u>	<u>2,885</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Moshe Kupferstein</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
6/21/2022	<u>New Issuance</u>	<u>24,038</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>WEBSIGHT INC-Emilech Wieder has voting control</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/14/2022	<u>New Issuance</u>	<u>12,019</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Go Drive NY Inc. -Israel Lundner has voting control</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
7/20/2022	<u>New Issuance</u>	<u>9,712</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Ron Gilboa</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)

6/20/2022	<u>New Issuance</u>	<u>12,019</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Moshe Mayer</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
6/7/2022	<u>New Issuance</u>	<u>11,510</u>	<u>Common</u>	<u>\$0.014</u>	<u>Yes</u>	<u>Moishe Kahan</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
8/9/2022	<u>New Issuance</u>	<u>28,846</u>	<u>Common</u>	<u>\$0.0104</u>	<u>Yes</u>	<u>Joel Schlesinger</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
8/16/2022	<u>New Issuance</u>	<u>121,154</u>	<u>Common</u>	<u>\$0.0104</u>	<u>Yes</u>	<u>Yosef Kaufman</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
8/25/2022	<u>New Issuance</u>	<u>12,019</u>	<u>Common</u>	<u>\$0.0104</u>	<u>Yes</u>	<u>Joel Banda</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
8/29/2022	<u>New Issuance</u>	<u>18,221</u>	<u>Common</u>	<u>\$0.0104</u>	<u>Yes</u>	<u>Ronald Pasternak</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
8/31/2022	<u>New Issuance</u>	<u>120,192</u>	<u>Common</u>	<u>\$0.0104</u>	<u>Yes</u>	<u>David Ginzberg</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
9/06/2022	<u>New Issuance</u>	<u>18,202</u>	<u>Common</u>	<u>\$0.0104</u>	<u>Yes</u>	<u>Itamar Cohen</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
9/07/2022	<u>New Issuance</u>	<u>76,010</u>	<u>Common</u>	<u>\$0.0104</u>	<u>Yes</u>	<u>Hannya Yosef Rabinowitz</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
9/07/2022	<u>New Issuance</u>	<u>415,385</u>	<u>Common</u>	<u>\$0.0104</u>	<u>Yes</u>	<u>Itzhak Zeev Soloweitzik</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
9/08/2022	<u>New Issuance</u>	<u>9,615</u>	<u>Common</u>	<u>\$0.0104</u>	<u>Yes</u>	<u>Aharon Cohen</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
9/08/2022	<u>New Issuance</u>	<u>96,154</u>	<u>Common</u>	<u>\$0.0104</u>	<u>Yes</u>	<u>Dina Hemed</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
9/08/2022	<u>New Issuance</u>	<u>48,077</u>	<u>Common</u>	<u>\$0.0104</u>	<u>Yes</u>	<u>Raphael Kook</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
9/08/2022	<u>New Issuance</u>	<u>60,697</u>	<u>Common</u>	<u>\$0.0104</u>	<u>Yes</u>	<u>Aharon Yaffe</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
9/09/2022	<u>New Issuance</u>	<u>48,077</u>	<u>Common</u>	<u>\$0.0104</u>	<u>Yes</u>	<u>Chaim Ginzberg</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
9/12/2022	<u>New Issuance</u>	<u>48,077</u>	<u>Common</u>	<u>\$0.0104</u>	<u>Yes</u>	<u>Rahamim Mordechai Arie</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
9/12/2022	<u>New Issuance</u>	<u>56,250</u>	<u>Common</u>	<u>\$0.0104</u>	<u>Yes</u>	<u>Zalman Eisenberger</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
9/12/2022	<u>New Issuance</u>	<u>206,370</u>	<u>Common</u>	<u>\$0.0104</u>	<u>Yes</u>	<u>Yehoshua Asher Rabinovitz</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
9/13/2022	<u>New Issuance</u>	<u>379,808</u>	<u>Common</u>	<u>\$0.0104</u>	<u>Yes</u>	<u>Sholom N Gottdiener</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)

9/13/2022	<u>New Issuance</u>	<u>2,981</u>	<u>Common</u>	<u>\$0.0104</u>	<u>Yes</u>	<u>Prime Selection Inc. -Maurice Rosenberg has voting control</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
9/14/2022	<u>New Issuance</u>	<u>32,500</u>	<u>Common</u>	<u>\$0.0104</u>	<u>Yes</u>	<u>Binyomin Fishman</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
9/14/2022	<u>New Issuance</u>	<u>121,394</u>	<u>Common</u>	<u>\$0.0104</u>	<u>Yes</u>	<u>Yaacov Aharon Kaizer</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
9/15/2022	<u>New Issuance</u>	<u>31,500</u>	<u>Common</u>	<u>\$0.0104</u>	<u>Yes</u>	<u>Morton Fishman</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
9/15/2022	<u>New Issuance</u>	<u>31,500</u>	<u>Common</u>	<u>\$0.0104</u>	<u>Yes</u>	<u>MNHF 12-11 TRUST -Morton Mordechai Fishman has voting control</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
9/16/2022	<u>New Issuance</u>	<u>18,030</u>	<u>Common</u>	<u>\$0.0104</u>	<u>Yes</u>	<u>DINI WIGS LLC -Eitzik Weinberg has voting control</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
9/19/2022	<u>New Issuance</u>	<u>24,539</u>	<u>Common</u>	<u>\$0.0104</u>	<u>Yes</u>	<u>David Nahari</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
9/20/2022	<u>New Issuance</u>	<u>4,856</u>	<u>Common</u>	<u>\$0.0104</u>	<u>Yes</u>	<u>Menashe Szegedin</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
10/03/2022	<u>New Issuance</u>	<u>242,308</u>	<u>Common</u>	<u>\$0.0104</u>	<u>Yes</u>	<u>Daniel Simon Black</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
10/07/2022	<u>New Issuance</u>	<u>2,424</u>	<u>Common</u>	<u>\$0.0104</u>	<u>Yes</u>	<u>Dovid Perlstein</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
10/24/2022	<u>New Issuance</u>	<u>67,308</u>	<u>Common</u>	<u>\$0.0104</u>	<u>Yes</u>	<u>Meir Moshe Kirshenbaum</u>	<u>Private Placement</u>	<u>Restricted</u>	Reg D 506(b)
Shares Outstanding on Date of This Report:									
<u>Ending Balance</u>									
<u>Ending Balance:</u>									
Date 10/31/2022	Common: 14,883,665								
		Preferred: 837,999							

Example: A company with a fiscal year end of December 31st, in addressing this item for its quarter ended June 30, 2021, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2019 through June 30, 2021 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements: ☒

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____

Use the space below to provide any additional details, including footnotes to the table above:

4) Financial Statements

A. The following financial statements were prepared in accordance with:

- ☒ U.S. GAAP
☐ IFRS

B. The financial statements for this reporting period were prepared by (name of individual)⁴:

Name: David Natan
Title: Consultant
Relationship to Issuer: None

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance Sheet;
D. Statement of Income;
E. Statement of Cash Flows;
F. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
G. Financial notes; and
H. Audit letter, if audited

⁴ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

We are putting together our business plan at the current time. On January 26, 2023 the Company received a purchase order from a leading luggage retailer for two types of luggage amounting to a total of \$925,000. The Company is in the process of working with a manufacturer to produce the luggage.

B. Please list any subsidiaries, parents, or affiliated companies.

None

C. Describe the issuers' principal products or services.

Distribution and manufacturing of luggage

6) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The Company leases office space on demand at 80 Broad St. New York, New York.

7) Company Insiders (Officers, Directors, and Control Persons)

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% or more of any class of the issuer's securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
<u>Issamar Ginzberg</u>	CEO	Brooklyn, New York	279,300	A-1 Preferred Stock	33.3%	Each share of preferred stock is convertible into 1,000 shares of common stock
<u>Israel Moshe Levy</u>	Owner of more than 5%	Jerusalem, Israel	279,300	A-1 Preferred Stock	33.3%	Each share of preferred stock is convertible into 1,000 shares of common stock
Shmuel Rotbard		Jerusalem, Israel	279,300	A-1 Preferred Stock	33.3%	Each share of preferred stock is convertible into 1,000 shares of common stock
<u>Issamar Ginzberg</u>	CEO	Brooklyn, New York	2,054,347	Common	13.8%	
<u>Israel Moshe Levy</u>	Owner of more than 5%	Jerusalem, Israel	2,054,347	Common	13.8%	

Shmuel Rotbard	Owner of more than 5%	Jerusalem, Israel	2,054,347	Common	13.8%	

8) Legal/Disciplinary History

A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

No

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

No

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

No

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

No

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

McMurdo Law Group, LLC

Matthew McMurdo, Esq.

matt@nannaronelaw.com,

1185 Avenue of the Americas
3rd Floor
New York, New York 10036
917-318-2865

Accountant or Auditor

BF Borgers CPA PC

5400 West Cedar Avenue
Lakewood, CO 80226
303.953.1454
contact@bfbcpa.us
www.bfbcpa.us

Investor Relations

None

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

Name: _____
Firm: _____
Nature of Services: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Issamar Ginzberg certify that:

1. I have reviewed this Annual disclosure statement of Fuss Brands Corp.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

1/30/23

/s/ Issamar Ginzberg [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, Issamar Ginzberg certify that:

1. I have reviewed this Annual disclosure statement of Fuss brands Corp;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

01/30/23

/s/ Issamar Ginzberg [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

Report of Independent Registered Public Accounting Firm	F-2
---	-----

Balance Sheets as of October 31, 2022 and October 31, 2021	F-3
--	-----

Statement of Operations for the Year Ended October 31, 2022 and October 31, 2021	F-4
--	-----

Statement of Changes in Stockholders' Deficit for the Year Ended October 31, 2022 and October 31, 2021	F-5
--	-----

Statement of Cash Flows for the Year Ended October 31, 2022 and October 31, 2021	F-6
--	-----

Notes to the Financial Statements	F-7
---	-----

F-1

Report of Independent Registered Public Accounting Firm

To the shareholders and the board of directors of Fuss Brands Corp.

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Fuss Brands Corp. as of October 31, 2022 and 2021, the related statements of operations, stockholders' equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of October 31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States.

Substantial Doubt about the Company's Ability to Continue as a Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses from operations and has a significant accumulated deficit. In addition, the Company continues to experience negative cash flows from operations. These factors raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

Critical Audit Matter

Critical audit matters are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.

We determined that there are no critical audit matters.

/S/ BF Borgers CPA PC (PCAOB ID 5041)

We have served as the Company's auditor since 2021
Lakewood, CO
January 27, 2023

F-2

FUSS BRANDS CORP. BALANCE SHEETS

	October 31, 2022	October 31, 2021
ASSETS		
Cash	\$ 35,539	\$ -
Total Assets	\$ 35,539	\$ -

LIABILITIES & STOCKHOLDERS' DEFICIT

Accounts payable and accrued liabilities	\$ 1,045	\$ -
Notes payable-related party	98,381	31,438
Total current liabilities	99,426	31,438
Total liabilities	99,426	31,438

Commitments and contingencies	-	-
-------------------------------	---	---

Stockholders' Deficit		
Preferred stock Series A, \$0.001 par value, 2,500,000 shares authorized, 837,899 and -0- shares issued and outstanding as of October 31, 2022 and October 31, 2021	838	1,000
Common stock, \$0.001 par value 1,000,000,000, shares authorized, 14,883,665 and 1,432,290 shares issued and outstanding as of October 31, 2022 and October 31, 2021	14,884	1,432
Additional paid-in capital	12,170,928	12,033,367
Discount on common stock	(75,889)	-
Accumulated deficit	(12,174,648)	(12,067,237)
Total Stockholders' (Deficit)	(63,887)	(31,438)
Total Liabilities and Stockholders' (Deficit)	\$ 35,539	\$ -

The accompanying notes are an integral part of these financial statements.

F-3

**FUSS BRANDS CORP.
STATEMENTS OF OPERATIONS**

October 31,	October 31,
2022	2021
<hr/>	<hr/>

Revenue	\$	-	\$	-
Operating Expenses:				
Administrative expenses		107,411		325,088
Total operating expenses		107,411		325,088
(Loss) from operations		(107,411)		(325,088)
Other expense		-		-
Other (expense) net		-		-
Income (loss) before provision for income taxes		(107,411)		(325,088)
Tax Provision		-		-
Net (Loss)	\$	(107,411)	\$	(325,088)
Basic and diluted (loss) per common share	\$	(0.01)	\$	(0.23)
Weighted average number of shares outstanding		7,666,944		1,432,290

The accompanying notes are an integral part of these financial statements.

F-4

**FUSS BRANDS CORP.
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY**

	Preferred Stock-Series A		Common Stock		Discount on Common	Paid in	Accumulated	Total
	Shares	Value	Shares	Value	Stock	Capital	Deficit	Stockholders' Equity
Balance, October 31, 2020	-	\$ -	1,432,290	\$ 1,432	\$ -	\$11,740,717	\$ (11,742,149)	\$ -

Net income (loss)							(325,088)	(325,088)
-------------------	--	--	--	--	--	--	-----------	-----------

Issuance of preferred stock for services to related party	1,000,000	1,000				249,000		250,000
---	-----------	-------	--	--	--	---------	--	---------

Capital contributions by former CEO						43,650		43,650
-------------------------------------	--	--	--	--	--	--------	--	--------

Balance, October 31, 2021	1,000,000	\$ 1,000	1,432,290	\$ 1,432	\$ -	\$12,033,367	\$ (12,067,237)	\$ (31,438)
---------------------------	-----------	----------	-----------	----------	------	--------------	-----------------	-------------

	Preferred Stock-Series A		Common Stock		Discount on Common	Paid in	Accumulated	Total Stockholders'
	Shares	Value	Shares	Value	Stock	Capital	Deficit	Equity
Balance, October 31, 2021	1,000,000	\$ 1,000	1,432,290	\$ 1,432	\$ -	\$12,033,367	\$ (12,067,237)	\$ (31,438)

Net income (loss)							(107,411)	(107,411)
-------------------	--	--	--	--	--	--	-----------	-----------

Conversion of Series A Preferred to common stock	(162,101)	(162)	6,234,654	6,235		(6,072)		-
--	-----------	-------	-----------	-------	--	---------	--	---

Misc adjustment to reflect rounding on reverse split			73	-				-
--	--	--	----	---	--	--	--	---

Private placement of common shares			7,216,647	7,217	(75,889)	143,634		74,962
------------------------------------	--	--	-----------	-------	----------	---------	--	--------

Balance, October 31, 2022	837,899	\$ 838	14,883,665	\$ 14,884	\$ (75,889)	\$12,170,928	\$ (12,174,648)	\$ (63,887)
---------------------------	---------	--------	------------	-----------	-------------	--------------	-----------------	-------------

The accompanying notes are an integral part of these financial statements.

F-5

**FUSS BRANDS CORP.
STATEMENTS OF CASH FLOWS**

	October 31, 2022	October 31, 2021
Cash Flows From Operating Activities:		
Net (loss)	\$ (107,411)	\$ (325,088)
Adjustments to reconcile net income to net cash provided by (used for) operating activities: Stock based compensation		250,000
Changes in operating assets and liabilities		
Accounts payable and accrued liabilities	1,045	
Net cash (used for) operating activities	(106,366)	(75,088)
Cash Flows From Investing Activities:		
Net cash provided by (used for) investing activities	-	-
Cash Flows From Financing Activities:		
Private placement of common shares, net of discount below par value	74,962	-
Notes payable related party	66,943	75,088
Net cash provided by financing activities	141,905	75,088
Net Increase In Cash	35,539	-
Cash At The Beginning Of The Period	-	-
Cash At The End Of The Period	\$ 35,539	\$ -
Supplemental disclosure of cash flow information:		
Cash paid for interest	\$ -	\$ -

Cash paid for taxes	\$	-	\$	-
---------------------	----	---	----	---

Supplemental disclosure of cash flow information:

Capital contribution by former related party	\$	-	\$	43,650
--	----	---	----	--------

The accompanying notes are an integral part of these financial statements.

F-6

**NOTES TO FINANCIALS STATEMENTS FOR THE
PERIOD ENDED October 31, 2022**

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

Fuss Brands Corp, f/k/a China Botanic Pharmaceutical Inc. (“the Company,” “we” “us”) was incorporated in the State of Nevada on August 18, 1988, originally under the corporate name of Solutions, Incorporated. It was inactive until August 16, 1996, when it changed its corporate name to Suarro Communications, Inc, and engaged in the business of providing internet-based business services. This line of business was discontinued in 2006, and the Company became a non-operating public company. The Company underwent a number of corporate name changes as follows:

June 1997	ComTech Consolidation Group, Inc
February 1999	E-Net Corporation
May 1999	E-Net Financial Corporation
January 2000	E-Net.Com Corporation
February 2000	E-Net Financial.Com Corporation
January 2002	Anza Capital, Inc (“Anza”)
June 2006	Renhuang Pharmaceuticals, Inc.
October 2010	China Botanic Pharmaceutical Inc.

The Company had been inactive since September 2012.

On February 4, 2021, as a result of a custodianship in Clark County, Nevada, Case Number: A-20-827231-B Custodian Ventures LLC (“Custodian”) was appointed custodian of the Company. On the same date, Custodian appointed David Lazar as the Company’s Chief Executive Officer, President, Secretary, Chief Financial Officer, Chief Executive Officer, and Chairman of the Board of Directors.

On August 24, 2021, as a result of a private transaction, 1,000,000 shares of Series A-1 Preferred Stock, \$0.001 par value per share (the “Shares”) of the Company, were transferred from Custodian Ventures, LLC to Issamar Ginzberg, Israel Moshe Levy, Shmuel Rotbard, and Benjamin Levin (collectively, the “Purchasers”). As a result, the Purchasers became holders of approximately 96% of the voting rights of the issued and outstanding share capital of the Company on a fully diluted basis of the Company and became the controlling

shareholder. The consideration paid for the Shares was \$250,000. The source of the cash consideration for the Shares was personal funds. In connection with the transaction, David Lazar released the Company from all debts owed to him and/or Custodian Ventures, LLC.

On August 24, 2021, the existing director and officer resigned immediately. Accordingly, David Lazar, serving as a director and an officer, ceased to be the Company's Chief Executive Officer, Chief Financial Officer, President, Treasurer, Secretary, and Director. At the effective date of the transfer, Issamar Ginzberg consented to act as the new Chief Executive Officer, Chief Financial Officer, President, Treasurer, Secretary, and a Director of the Company,

On July 14, 2022, China Botanic Pharmaceuticals Inc. amended its articles of incorporation to change its name to Fuss Brands Corp. (the "Name Change"). The change was made in anticipation of entering into a new line of business operations.

On July 13, 2022, the Company amended its articles of incorporation to reverse split its common stock at a rate of 1 for 26 (the "Reverse").

On July 22, 2022, FINRA declared the Name Change and the Reverse effective. Also on July 28, 2022, the Company was informed by FINRA that the Company's ticker symbol would be changed to FBDS in twenty business days.

The Company's year-end is October 31.

F-7

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying financial statements have been prepared in accordance with the Financial Accounting Standards Board ("FASB") "FASB Accounting Standard Codification™" (the "Codification") which is the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with generally accepted accounting principles ("GAAP") in the United States.

Going Concern

The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the twelve months following the date of these financial statements. As of October 31, 2022, the Company had negative working capital of \$63,997 and an accumulated deficit of \$12,174,648.

Because the Company does not expect that existing operational cash flow will be sufficient to fund presently anticipated operations, this raises substantial doubt about the Company's ability to continue as a going concern. Therefore, the Company will need to raise additional funds and is currently exploring alternative sources of financing. Recently the Company has been funded by related party shareholders and officers. Historically, the Company raised capital through private placements, to finance working capital needs and may attempt to raise capital through the sale of common stock or other securities and obtaining some short-term loans. The Company will be required to continue to do so until its operations become profitable. Also, the Company has, in the past, paid for consulting services with its common stock to maximize working capital, and intends to continue this practice where feasible.

Use of Estimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to income taxes and contingencies. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that

are believed to be reasonable given the quality of information available as of the date of these financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.

Reverse Stock Split

On July 26, 2022, the Company effected a 1 for 26 reverse stock split of its common stock. All common stock amounts and references have been retroactively adjusted for all figures present to reflect this split unless specifically stated otherwise

Cash and cash equivalents

The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. As of October 31, 2022, and October 31, 2021, the Company had \$35,539 and -0- cash on hand, respectively.

F-8

Income taxes

The Company accounts for income taxes under FASB ASC 740, “Accounting for Income Taxes”. Under FASB ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under FASB ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. FASB ASC 740-10-05, “Accounting for Uncertainty in Income Taxes” prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities.

The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. The Company assesses the validity of its conclusions regarding uncertain tax positions quarterly to determine if facts or circumstances have arisen that might cause it to change its judgment regarding the likelihood of a tax position’s sustainability under audit.

Net Loss per Share

Net loss per common share is computed by dividing net loss by the weighted average common shares outstanding during the period as defined by Financial Accounting Standards, ASC Topic 260, “Earnings per Share.” Basic earnings per common share (“EPS”) calculations are determined by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding.

Recent Accounting Pronouncements

There are no recent accounting pronouncements that impact the Company’s operations.

NOTE 3 – RELATED PARTY TRANSACTIONS

During the fiscal year ended October 31, 2021, the Custodian extended to the Company an interest-free demand loan of \$43,650 to help fund the Company’s expenses. On August 24, 2021, as part of the transaction in which Custodian Ventures sold its 1,000,000 shares of Series A Preferred Stock described in Note 1. “Organization and Description of Business”, Custodian agreed to forgive any amounts due to Custodian. As a result, the \$43,650 due to Custodian was reclassified as a capital contribution through Equity and had no impact on the Company’s Statement of Operations for the period ended October 31, 2021.

Subsequent to August 24, 2021, the funding for the Company has been provided by Issamar Ginzberg, Shmuel Rotbard, and Israel Moshe Levy in the form of interest-free demand loans. As of October 31, 2022, and October 31, 2021, the balance of related parties loans was \$98,381 and \$31,348 respectively.

F-9

NOTE 4 – EQUITY

Common Stock

The Company has authorized 1,000,000,000 shares of \$0.001 par value, common stock.

On July 26, 2022, the Company effected a 1 for 26 reverse stock split of its common stock. All common stock amounts and references have been retroactively adjusted for all figures present to reflect this split unless specifically stated otherwise

During the three months ended July 31, 2022, the Company raised \$50,593 in gross proceeds from the sale of 4,864,668 shares of common stock. Since these shares were sold at \$0.014 prior to the reverse split, which was below the par value of \$0.001, the Company recorded a discount on common stock of \$75,889 which reduced the Company's equity.

During the three months ended October 31, 2022, the Company raised \$24,369 in gross proceeds from the sale of 2,351,980 shares of common stock or an average price of \$0.0104.

As of October 31, 2022, and October 31, 2021, there were 14,883,665 and 1,432,290 shares of common stock issued and outstanding, respectively.

Preferred Stock

The Company has 2,500,000 shares of Series A Preferred Stock, \$0.001 par value, authorized

During the three months ended April 30, 2022 split, 162,101 shares of Series A Preferred Stock were converted on a 1,000 to 1 ratio into 6,234,654 shares of common stock.

On June 23, 2021, the Company amended its Articles of Incorporation and designated 2,500,000 Preferred A-1 shares. On July 2, 2021, the Company awarded Custodian Ventures/David Lazar 1,000,000 Series A-1 Preferred Stock for services performed as Custodian. Each share of Series A-1 Preferred stock is convertible to 1,000 shares of common stock. Based on this conversion rate, Custodian would control approximately 96% of the Company. As a result, since this share issuance represented substantially all of the Company's value, the shares were valued at the purchase price of the Preferred Shares of \$250,000 on August 24, 2021. The \$250,000 was recognized as stock-based compensation, related party in the Company's Statement of Operations for the period ended October 31, 2021.

The attributes of the Series A Preferred Stock are as follows:

Subject to the rights of any existing series of Preferred Stock or to the rights of any series of Preferred Stock which may from time to time hereafter come into existence, the holders of shares of Series A-1 Preferred Stock shall be entitled to receive dividends, out of any assets legally available therefor, upon any payment of any dividend (payable other than in Common Stock or other securities and rights convertible into or entitling the holder thereof to receive, directly or indirectly, additional shares of Common Stock of the Corporation) on the Common Stock of the Corporation, as and if declared by the Board of Directors, as if the Series A-1 Preferred Stock had been converted into Common Stock.

F-10

Liquidation Preference.

In the event of any liquidation, dissolution, or winding up of the Corporation, either voluntary or involuntary, the holders of the Series A-1 Preferred Stock shall be entitled to receive, prior and in preference to any distribution of any of the assets of the Corporation to the holders of Common Stock, or any other series or class of common stock of the Corporation, whether now in existence or hereafter created by amendment to the articles of incorporation of the Corporation or by a certificate of designation, by reason of their ownership thereof, and senior, prior, and in preference to any other series or class of preferred stock of the Corporation, whether now in existence or hereafter created by amendment to the articles of incorporation of the Corporation or by a certificate of designation, an amount per share equal to the price per share actually paid to the Corporation upon the initial issuance of the Series A-1 Preferred Stock (each, the “the Original Issue Price”) for each share of Series A-1 Preferred Stock then held by them, plus declared but unpaid dividends. Unless the Corporation can establish a different Original Issue Price in connection with a particular sale of Series A-1 Preferred Stock, the Original Issue Price shall be \$0.001 per share for the Series A-1 Preferred Stock. If, upon the occurrence of any liquidation, dissolution, or winding up of the Corporation, the assets and funds thus distributed among the holders of the Series A-1 Preferred Stock shall be insufficient to permit the payment to such holders of the full aforesaid preferential amounts, then, the entire assets and funds of the corporation legally available for distribution shall be distributed first to the Series A-1 Preferred Stock, and then ratably among the holders of each other series of Preferred Stock in proportion to the preferential amount each such holder is otherwise entitled to receive.

The Series A-1 Preferred Stock shares are non-redeemable other than upon the mutual agreement of the Corporation and the holder of shares to be redeemed and even in such case only to the extent permitted by this Certificate of Designation, the Corporation’s Articles of Incorporation, and applicable law.

Conversion.

The holders of the Series A-1 Preferred Stock, shall have conversion rights as follows (the “Conversion Rights”):

Right to Convert.

Subject to Section 4(c), each share of Series A-1 Preferred Stock shall be convertible, at the option of the holder(s) thereof only, at any time after the date of issuance of such share, at the office of the Corporation or any transfer agent for such stock, into one thousand (1,000) fully paid and nonassessable shares of Common Stock (the “Series A-1 Conversion Ratio”).

During the three months ended April 30, 2022, 162,101 shares of Series A Preferred Stock were converted on a 1,000 to 1 ratio into 6,234,654 shares of Common Stock.

As of October 31, 2022, and October 31, 2021, there 837,899 and 1,000,000 shares of Series A Preferred Stock were issued and outstanding, respectively.

NOTE 5 – COMMITMENTS AND CONTINGENCIES

The Company did not have any contractual commitments as of October 31, 2022, and October 31, 2021.

NOTE 6 – SUBSEQUENT EVENTS

Subsequent to October 31, 2022 the Company sold 380,289 shares to investors and raised approximately \$3,955 in proceeds.

On January 26, 2023 the Company received a purchase order from a leading luggage retailer for two types of luggage amounting to a total of \$925,000. The Company is in the process of working with a manufacturer to produce the luggage.

